statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the...

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial...

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the...

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Volume	1.01M
52-Wk High	$3.77
52-Wk Low	$1.05

ACET Adicet Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals